YKL-05-099 NEW
| Price | $68 | $123 | $189 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: YKL-05-099 | CAS No.: 1936529-65-5 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | YKL-05-099 |
| Description | YKL-05-099 is a salt-inducible kinase (SIK) inhibitor. It can inhibit the activity of SIK1 (IC50: 10 nM) and SIK3 (IC50: 30 nM), and has a slightly weaker inhibitory effect on SIK2 (IC50: 40 nM). [1] |
| In vitro | YKL-05-099 inhibits the production of the inflammatory cytokines TNFα, IL-6 and IL-12p40, and only modestly enhances IL-1β release in BMDCs stimulated with the yeast cell wall extract Zymosan A. YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM) and IL-10-enhancing activities (EC50=460 nM). YKL-05-099 binds to SIK1 and SIK3 (IC50s: 10 and 30 nM, respectively, in a competitive binding assay). Preincubating bone marrow-derived macrophages with YKL-05-099 decreases LPS stimulated phosphorylation of HDAC5 at the SIK-specific phosphorylation site Ser259 [1]. |
| In vivo | METHODS: YKL-05-099 (6, 18 mg/kg/d) was tested in surgically ovariectomized mice by intraperitoneal injection to see if it could increase cancellous bone mass in hypogonadal female mice. RESULTS YKL-05-099 treatment increased trabecular bone mass in the femur and L5 vertebrae of hypogonadal female mice, indicating that the agent does not cause significant defects in cortical bone mass. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (74.99 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.33 mM), Sonication is recommended. |
| Keywords | YKL-05-099 | YKL05099 | YKL 05 099 | SIK3 | SIK2 | SIK1 | Salt-inducible Kinase (SIK) | Inhibitor | inhibit |
| Inhibitors Related | YKL-06-061 | MRT 67307 dihydrochloride | Pterosin B | GLPG3970 | ARN-3236 | WH-4-025 | YKL-06-062 | HG-9-91-01 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Glycolysis Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Obesity Compound Library | Autophagy Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/25kg |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-02-25 | |
| $386.00/100μg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-29 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY